These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34990622)

  • 1. Preferentially expressed Antigen in MElanoma immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation.
    Fattori A; de la Fouchardière A; Cribier B; Mitcov M
    Hum Pathol; 2022 Mar; 121():19-28. PubMed ID: 34990622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors.
    Alomari AK; Tharp AW; Umphress B; Kowal RP
    J Cutan Pathol; 2021 Sep; 48(9):1115-1123. PubMed ID: 33660310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
    Bahmad HF; Oh KS; Alexis J
    J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
    Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
    J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
    Googe PB; Flanigan KL; Miedema JR
    Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of Preferentially Expressed Antigen in Melanoma Immunohistochemistry and Diagnostic Gene Expression-Profiling Assay in Challenging Melanocytic Proliferations.
    Casillas AC; Muhlbauer A; Barragan VA; Jefferson I; Speiser JJ
    Am J Dermatopathol; 2024 Mar; 46(3):137-146. PubMed ID: 38354382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic utility of combining PRAME and HMB-45 stains in primary melanocytic tumors.
    Rasic D; Korsgaard N; Marcussen N; Precht Jensen EM
    Ann Diagn Pathol; 2023 Dec; 67():152211. PubMed ID: 37717457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi.
    Lohman ME; Steen AJ; Grekin RC; North JP
    J Cutan Pathol; 2021 Jul; 48(7):856-862. PubMed ID: 33433032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
    Lezcano C; Jungbluth AA; Busam KJ
    Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review.
    Turner N; Ko CJ; McNiff JM; Galan A
    Am J Dermatopathol; 2024 Jan; 46(1):21-30. PubMed ID: 37982498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions.
    Lezcano C; Jungbluth AA; Busam KJ
    Surg Pathol Clin; 2021 Jun; 14(2):165-175. PubMed ID: 34023098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRAME and Historical Immunohistochemical Antibodies Ki-67, P16, and HMB-45 in Ambiguous Melanocytic Tumors.
    Mert M; Bozdogan O; Bozdogan N; Gamsızkan M; Safali M
    Am J Dermatopathol; 2024 Oct; 46(10):653-662. PubMed ID: 38916203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRAME Expression in Challenging Dermal Melanocytic Neoplasms and Soft Tissue Tumors With Melanocytic Differentiation.
    Kline N; Menge TD; Hrycaj SM; Andea AA; Patel RM; Harms PW; Chan MP; Bresler SC
    Am J Dermatopathol; 2022 Jun; 44(6):404-410. PubMed ID: 34991102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRAME Expression Correlates With Genomic Aberration and Malignant Diagnosis of Spitzoid Melanocytic Neoplasms.
    Gerami P; Benton S; Zhao J; Zhang B; Lampley N; Roth A; Boutko A; Olivares S; Busam KJ
    Am J Dermatopathol; 2022 Aug; 44(8):575-580. PubMed ID: 35503885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of PRAME immunohistochemistry compared with that of c-Kit, c-Myc, or cyclin D1 for the diagnosis of acral melanocytic tumors.
    Jung JM; Lee MY; Won CH; Chang SE; Lee MW; Lee WJ
    Pathol Int; 2023 Jan; 73(1):27-36. PubMed ID: 36468840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRAME expression in melanocytic lesions of the nail.
    Parra O; Linos K; Li Z; Yan S
    J Cutan Pathol; 2022 Jul; 49(7):610-617. PubMed ID: 35294053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRAME Expression in Junctional Melanocytic Proliferations of the Conjunctiva: A Potential Biomarker for Primary Acquired Melanosis/Conjunctival Melanocytic Intraepithelial Lesions.
    Huang YY; Hrycaj SM; Chan MP; Stagner AM; Patel RM; Bresler SC
    Am J Dermatopathol; 2022 Oct; 44(10):734-740. PubMed ID: 35475786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRAME expression by immunohistochemistry and reverse transcription quantitative PCR in conjunctival melanocytic lesions-a comprehensive clinicopathologic study of 202 cases and correlation of cytogenetics with PRAME expression in challenging conjunctival melanocytic lesions.
    Mudhar HS; Milman T; Stevenson S; Watson M; Kim J; Magan T; Salvi SM; Harley U; Lally SE; Shields CL
    Hum Pathol; 2023 Apr; 134():1-18. PubMed ID: 36804828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic utility of PRAME in distinguishing proliferative nodules from melanoma in giant congenital melanocytic nevi.
    Gill P; Prieto VG; Austin MT; Giubellino A; Torres-Cabala CA
    J Cutan Pathol; 2021 Nov; 48(11):1410-1415. PubMed ID: 34164835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRAME expression in genital melanocytic lesions - Potential diagnostic pitfall of intermediate expression in atypical genital nevi.
    Ng JKM; Choi PCL; Chow C; Li JJX; To KF
    Pathol Res Pract; 2024 Aug; 260():155404. PubMed ID: 38878667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.